JPS6445396A - Cyclosporins and medicinal use - Google Patents

Cyclosporins and medicinal use

Info

Publication number
JPS6445396A
JPS6445396A JP63149227A JP14922788A JPS6445396A JP S6445396 A JPS6445396 A JP S6445396A JP 63149227 A JP63149227 A JP 63149227A JP 14922788 A JP14922788 A JP 14922788A JP S6445396 A JPS6445396 A JP S6445396A
Authority
JP
Japan
Prior art keywords
residue
cyclosporins
mebmt
dihydro
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63149227A
Other languages
English (en)
Other versions
JPH0832724B2 (ja
Inventor
Boringeru Pietoro
Yakobu Berusuteruri Yohan
Furansowa Bore Jiyan
Kuriigeru Manfuretsuto
Gurin Peine Toreboru
Pee Toraberu Rune
Bedogeru Rooranto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878714090A external-priority patent/GB8714090D0/en
Priority claimed from GB878714100A external-priority patent/GB8714100D0/en
Priority claimed from GB878714118A external-priority patent/GB8714118D0/en
Priority claimed from GB878714098A external-priority patent/GB8714098D0/en
Priority claimed from GB878714125A external-priority patent/GB8714125D0/en
Priority claimed from GB878714093A external-priority patent/GB8714093D0/en
Priority claimed from GB878714115A external-priority patent/GB8714115D0/en
Priority claimed from GB878714119A external-priority patent/GB8714119D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JPS6445396A publication Critical patent/JPS6445396A/ja
Publication of JPH0832724B2 publication Critical patent/JPH0832724B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP63149227A 1987-06-17 1988-06-16 シクロスポリン類およびそれらの医薬用途 Expired - Lifetime JPH0832724B2 (ja)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
GB8714093 1987-06-17
GB878714100A GB8714100D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714118A GB8714118D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714098A GB8714098D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714090A GB8714090D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB8714125 1987-06-17
GB878714125A GB8714125D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714093A GB8714093D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB8714098 1987-06-17
GB8714100 1987-06-17
GB8714119 1987-06-17
GB8714090 1987-06-17
GB878714115A GB8714115D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714119A GB8714119D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB8714115 1987-06-17
GB8714118 1987-06-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP7208783A Division JP2772372B2 (ja) 1987-06-17 1995-08-16 シクロスポリン類およびそれらの医薬用途

Publications (2)

Publication Number Publication Date
JPS6445396A true JPS6445396A (en) 1989-02-17
JPH0832724B2 JPH0832724B2 (ja) 1996-03-29

Family

ID=27571252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP63149227A Expired - Lifetime JPH0832724B2 (ja) 1987-06-17 1988-06-16 シクロスポリン類およびそれらの医薬用途
JP7208783A Expired - Lifetime JP2772372B2 (ja) 1987-06-17 1995-08-16 シクロスポリン類およびそれらの医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP7208783A Expired - Lifetime JP2772372B2 (ja) 1987-06-17 1995-08-16 シクロスポリン類およびそれらの医薬用途

Country Status (21)

Country Link
US (1) US5525590A (ja)
EP (1) EP0296122B1 (ja)
JP (2) JPH0832724B2 (ja)
KR (1) KR970010927B1 (ja)
AT (1) ATE95193T1 (ja)
AU (1) AU614086B2 (ja)
CA (1) CA1338728C (ja)
CY (1) CY1939A (ja)
CZ (1) CZ411791A3 (ja)
DE (1) DE3884470T2 (ja)
DK (1) DK173873B1 (ja)
ES (1) ES2059558T3 (ja)
HK (1) HK152796A (ja)
HU (1) HU211678A9 (ja)
IE (1) IE62482B1 (ja)
IL (1) IL86751A (ja)
MY (1) MY103582A (ja)
NZ (1) NZ225041A (ja)
PT (1) PT87745B (ja)
SA (1) SA97170746A (ja)
SK (1) SK411791A3 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505872A (ja) * 1992-04-22 1995-06-29 ノバルティス・アクチエンゲゼルシャフト サイクロスポリン誘導体含有医薬組成物
JP2004536076A (ja) * 2001-06-05 2004-12-02 ノバルティス　アクチエンゲゼルシャフト Ｐ−ｇｐインヒビターおよび抗癲癇薬を含んでなる組合せ剤
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
JP2010280710A (ja) * 2001-10-19 2010-12-16 Isotechnika Inc シクロスポリン類似体の合成法
JP2011529451A (ja) * 2008-07-30 2011-12-08 アイソテクニカ ファーマ インク． 非免疫抑制性シクロスポリン類似体分子
US9714271B2 (en) 2010-12-15 2017-07-25 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283801A3 (en) * 1987-03-27 1990-05-30 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
CH679277A5 (ja) * 1989-02-09 1992-01-31 Sandoz Ag
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
HK1004520A1 (en) * 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
PT589843E (pt) 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9318612D0 (en) * 1993-09-08 1993-10-27 Sandoz Ltd An assay
US6187547B1 (en) 1993-09-08 2001-02-13 Novartis Ag Assay kit
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
SK164796A3 (en) 1994-11-03 1997-06-04 Dresden Arzneimittel Novel cyclosporine preparation forms for oral administration of and process for producing them
GR1002687B (el) * 1995-04-17 1997-05-06 Novartis Ag (Novartis Sa) (Novartis Inc.) Διαδικασια παραγωγης.
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
SK285019B6 (sk) * 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
AU750245B2 (en) * 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6673768B1 (en) 1997-10-16 2004-01-06 Board Of Regents, The University Of Texas System Transgenic animal models for cardiac hypertrophy and methods of use thereof (treating)
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
ATE404172T1 (de) 1998-12-30 2008-08-15 Dexcel Ltd Dispergierbares konzentrat zur verabreichung von cyclosporin
US6255280B1 (en) * 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
US20030087813A1 (en) * 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
CN100344648C (zh) * 2001-10-19 2007-10-24 伊索泰克尼卡股份有限公司 环孢菌素类似物混合物及其在制备免疫调节剂中的用途
IL160761A0 (en) 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
US7538084B2 (en) * 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
JP5080241B2 (ja) * 2004-04-08 2012-11-21 メルク セローノ ソシエテ アノニム Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
JP2008514702A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
JP2008515886A (ja) * 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
WO2006063470A1 (en) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites of cyclosporin analogs
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20080206287A1 (en) * 2006-09-18 2008-08-28 Reed John C Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
US8450281B2 (en) * 2007-01-04 2013-05-28 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
KR20110071014A (ko) 2008-10-17 2011-06-27 위스콘신 얼럼나이 리서어치 화운데이션 생물학적으로 활성인 알파-베타 펩티드의 제조 방법
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
KR20110111321A (ko) * 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
DE102009037551A1 (de) 2009-08-17 2011-02-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cyclosporinderivate
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
WO2012145427A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
JP2016538317A (ja) 2013-08-26 2016-12-08 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎を防止または治療するための新規シクロスポリン類似体
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
CA2996064C (en) 2015-08-18 2024-02-13 Novation Pharmaceuticals Inc. Benzopyran derivatives and uses thereof
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020014652A1 (en) * 2018-07-13 2020-01-16 New York University Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CN114208781B (zh) * 2022-01-20 2022-12-20 河南农业大学 一种抑制草地贪夜蛾龄期的方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56128725A (en) * 1980-02-14 1981-10-08 Sandoz Ag Full synthesization of cyclosporin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH614931A5 (ja) * 1975-11-04 1979-12-28 Sandoz Ag
US4210581A (en) * 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB8407618D0 (en) * 1984-03-23 1984-05-02 Sandoz Ltd Organic compounds
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56128725A (en) * 1980-02-14 1981-10-08 Sandoz Ag Full synthesization of cyclosporin

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505872A (ja) * 1992-04-22 1995-06-29 ノバルティス・アクチエンゲゼルシャフト サイクロスポリン誘導体含有医薬組成物
JP2004536076A (ja) * 2001-06-05 2004-12-02 ノバルティス　アクチエンゲゼルシャフト Ｐ−ｇｐインヒビターおよび抗癲癇薬を含んでなる組合せ剤
JP2010280710A (ja) * 2001-10-19 2010-12-16 Isotechnika Inc シクロスポリン類似体の合成法
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
JP2011529451A (ja) * 2008-07-30 2011-12-08 アイソテクニカ ファーマ インク． 非免疫抑制性シクロスポリン類似体分子
US9714271B2 (en) 2010-12-15 2017-07-25 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3

Also Published As

Publication number Publication date
DE3884470T2 (de) 1994-03-10
US5525590A (en) 1996-06-11
PT87745A (pt) 1988-07-01
SA97170746A (ar) 2005-12-03
IL86751A0 (en) 1988-11-30
HU211678A9 (en) 1995-12-28
ATE95193T1 (de) 1993-10-15
MY103582A (en) 1993-08-28
ES2059558T3 (es) 1994-11-16
CZ411791A3 (en) 1993-02-17
IE881807L (en) 1988-12-17
PT87745B (pt) 1992-10-30
AU1767988A (en) 1988-12-22
DK326588A (da) 1988-12-18
KR970010927B1 (ko) 1997-07-02
JPH0832724B2 (ja) 1996-03-29
HK152796A (en) 1996-08-16
DK326588D0 (da) 1988-06-15
IE62482B1 (en) 1995-02-08
CA1338728C (en) 1996-11-19
IL86751A (en) 1994-02-27
AU614086B2 (en) 1991-08-22
EP0296122A3 (en) 1990-06-20
JP2772372B2 (ja) 1998-07-02
JPH0848696A (ja) 1996-02-20
DE3884470D1 (de) 1993-11-04
CY1939A (en) 1997-05-16
SK411791A3 (en) 1995-07-11
NZ225041A (en) 1991-03-26
KR890000519A (ko) 1989-03-15
EP0296122B1 (en) 1993-09-29
EP0296122A2 (en) 1988-12-21
DK173873B1 (da) 2002-01-21

Similar Documents

Publication Publication Date Title
JPS6445396A (en) Cyclosporins and medicinal use
DE3868886D1 (de) Fettsaeure-zusammensetzungen.
HUT68251A (en) Antiviral 2-ethyl-1h-imidazo(4,5-c)quinolin-4-amines and pharmaceutical compositions containing them
EP0307128A3 (en) Azithromycin and derivatives as antiprotozoal agents
MY111201A (en) New imidazopyridines
NZ226845A (en) 2', 3'-dideoxy-2'-fluoronucleosides; pharmaceutical compositions and processes for their preparation
EP0296573A3 (en) Novel nucleosides, their preparation and pharmaceutical novel nucleosides, their preparation and pharmaceutical compositions compositions
GR3006366T3 (ja)
IL80201A0 (en) Labdane derivatives,processes for their preparation and pharmaceutical compositions containing them
EP0334853A4 (en) LIGHT STEROIDS WITH ANTI-INFLAMMATORY ACTIVITY.
FI945696A0 (fi) Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
DE3854158D1 (de) Nucleosid-analoge.
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
GR3004272T3 (ja)
DK1707568T3 (da) Farmaceutisk sammensætning til anvendelse i behandlingen af ovariecancer hos et menneske, der har sygdommen
MY103900A (en) 6-substituted 2'', 3''-dideoxynucleosides and pharmaceutical compositions

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080329

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090329

Year of fee payment: 13

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090329

Year of fee payment: 13